Genethon welcomes interim data of a phase I / II clinical trial with a gene therapy product developed in its laboratories.
At the 12-week timepoint, the first 3 children treated show early signs of efficacy.
Genethon welcomes interim data of a phase I / II clinical trial with a gene therapy product developed in its laboratories.
At the 12-week timepoint, the first 3 children treated show early signs of efficacy.
